COAG (Hemab Therapeutics Holdings) Moat Score: 4/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.52
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings Moat Score?

Hemab Therapeutics Holdings COAG +3.48% 11 Moat Score is 4 as of Aug. 04, 2026. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,394 Biotechnology companies, Hemab Therapeutics Holdings ranks better than 88.81% on this metric.

Hemab Therapeutics Holdings has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Hemab Therapeutics Holdings has Narrow Moat: Hemab Therapeutics has a modest moat due to its valuable intellectual property and patents in the biotech sector. However, its market share and brand strength are not yet robust enough to elevate it to a strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Hemab Therapeutics Holdings might have Narrow Moat - Discernible but modest moat.

Hemab Therapeutics Holdings  (NAS:COAG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Hemab Therapeutics Holdings Moat Score Related Terms

COAG vs ZLAB, SLS, IOVA: Moat Score Comparison

For the Biotechnology subindustry, Hemab Therapeutics Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemab Therapeutics Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Hemab Therapeutics Holdings's Moat Score falls into.


COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Hemab Therapeutics Holdings (COAG) has a Moat Score of 4 as of Aug. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #156 out of 1394 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Hemab Therapeutics Holdings' Moat Score too high?
Hemab Therapeutics Holdings' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Hemab Therapeutics Holdings' value of 4 is 100% above this industry median. Based on the distribution chart, Hemab Therapeutics Holdings ranks #156 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Moat Score compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #156 out of 1394 companies for Moat Score. This places Hemab Therapeutics Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Hemab Therapeutics Holdings' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemab Therapeutics Holdings's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemab Therapeutics Holdings's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Moat Score is 4 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.52
Price